Hirata Y, Uchihashi M, Fujita T, Matsukura S, Motoyama T, Kaku M, Koshimizu K
Endocrinol Jpn. 1983 Oct;30(5):601-7. doi: 10.1507/endocrj1954.30.601.
Using seventeen human tumor cell lines derived from a variety of tissues, specific binding sites for epidermal growth factor (EGF), a mouse submandibular gland-derived growth factor, has been characterized. A significant amount of membrane-bound EGF receptors, although considerably varied, was demonstrated in all the tumor cell lines studied. Epidermoid carcinoma appeared to have more EGF receptors than adenocarcinoma. One small cell carcinoma of the lung, one choriocarcinoma of the stomach and three bone tumors also possessed EGF receptors comparable to those of epidermoid carcinoma, while one adenoacanthoma of the stomach had less EGF receptors comparable to adenocarcinoma. Among a variety of phorbol esters tested, tetradecanoyl phorbol acetate, a potent tumor promotor, was shown to be the most effective compound in inhibiting 125I-labeled EGF binding to its receptors. Our results indicate that human tumor cells contain varying amounts of membrane-bound receptors for EGF and that phorbol esters interact with these EGF receptor sites. However, the relationship between EGF receptor sites on tumor cells and cellular proliferation and/or differentiation awaits further study.
利用从多种组织中获得的17种人类肿瘤细胞系，对源自小鼠颌下腺的生长因子——表皮生长因子（EGF）的特异性结合位点进行了表征。在所有研究的肿瘤细胞系中均证实存在大量膜结合型EGF受体，尽管其数量差异很大。表皮样癌似乎比腺癌具有更多的EGF受体。1例肺小细胞癌、1例胃绒毛膜癌和3例骨肿瘤也具有与表皮样癌相当的EGF受体，而1例胃腺棘皮癌的EGF受体数量则与腺癌相当但较少。在所测试的多种佛波酯中，强效肿瘤促进剂十四酰佛波醇乙酸酯被证明是抑制125I标记的EGF与其受体结合的最有效化合物。我们的结果表明，人类肿瘤细胞含有不同数量的膜结合型EGF受体，并且佛波酯与这些EGF受体位点相互作用。然而，肿瘤细胞上的EGF受体位点与细胞增殖和/或分化之间的关系有待进一步研究。
